Apnimed Stock

apnimed.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $208.02MM

Apnimed, founded in 2017, is a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, MA, the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Register To Buy and Sell Shares

For more details on financing and valuation for Apnimed, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Apnimed’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Apnimed.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Dennis Molnar
Chief Operating Officer
Luigi Montemurro MD
Co-Founder & Chief Scientific Officer
Barry Wohl
Chief Business Officer
Rob Rode
Chief Commercial Officer
Andrew Wellman MD
Co-Founder & Advisor
Ron Farkas Ph.D
Chief Medical Officer
Lawrence Miller MD
Founder & Chief Executive Officer
Michael Rogers
Chief Financial Officer

Board Members

Chris Dimitropoulos
Alpha Wave Global
Isaac Cheng MD
Morningside Group
Stefan Larson Ph.D
Sectoral Asset Management

Frequently Asked Questions About Apnimed’s Stock

plusminus
Can you buy Apnimed’s stock?
Apnimed is not publicly traded on NYSE or NASDAQ in the U.S. To buy Apnimed’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Apnimed’s stock?
Yes, you can sell stock of a private company like Apnimed. Forge can help you sell your Apnimed stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Apnimed’s stock price?
Apnimed is a privately held company and therefore does not have a public stock price. However, you may access Apnimed’s private market stock price with Forge Data.
plusminus
What is Apnimed’s stock ticker symbol?
Apnimed does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)
Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that it has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million.
Updated on: Apr 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.